GEFTINAT吉非替尼片剂说明书全文(中英对照翻译)

GEFTINAT吉非替尼片剂说明书全文（中英对照翻译）Hepatic Impairment: The influence of hepatic metastases with elevation Table 1: Demographic and Disease Characteristics INDICATIONS AND USAGE For the use only of a Cancer Specialist or a Hospital or an Institution of serum aspartate aminotransferase (AST/SGOT), alkaline phosphatase, Gefitinib Dose GEFITINAT is indicated as monotherapy for the treatment of patients GEFTINAT* and bilirubin has been evaluated in patients with normal (14 patients), 250 mg/day 500 mg/day with locally advanced or metastatic non-small cell lung cancer after (Gefitinib Tablets IP) moderately elevated (13 patients) and severely elevated (4 patients) Characteristic N=66(%) N=76(%) failure of both platinum-based and docetaxel chemotherapies. levels of one or more of these biochemical parameters. Patients with --------------------------------------------------------------------------- The effectiveness of Gefitinib is based on objective response rates (see Composition moderately and severely elevated biochemical liver abnormalities had Age Group CLINICAL PHARMACOLOGY - Clinical Studies section). There are no Each film coated tablet contains: Gefitinib IP 250 mg gefitinib pharmacokinetics similar to individuals without liver 18-64controlled trials demonstrating a clinical benefit, such as improvement years 43 (65) 43 (57) abnormalities (see PRECAUTIONS section). in disease-related symptoms or increased survival. 64-74 years 19 (29) 30 (39) DESCRIPTION Results from two large, controlled, randomized trials in first- line 75 years andabove 4 (6) 3 (4) GEFTINAT (gefitinib tablets IP) contain 250 mg of gefitinib IP and are Renal Impairment: No clinical studies were conducted with Gefitinib in Sex treatment of non-small cell lung cancer showed no benefit from adding available as reddish brown film-coated tablets engraved with GEFTINAT patients with severely compromised renal function (see PRECAUTIONS Male 38 (58) 41 (54) GEFTINAT to doublet, platinum-based chemotherapy. Therefore, on one side and 250 on another side tor daily oral administration. section). Gefitinib and its metabolites are not significantly excreted via GEFTINAT is not indicated for use in this setting. Female 28 (42) 35(46) Gefitinib is an anilinoquinazoline with the chemical name 4-Quinazolin the kidney(<4%). Race amine, N-(3-chloro-4-fluorophenyl)-7-methoxy-6-[3-4-morpholin] CONTRAINDICATIONS White 61 (92) 68(89) propoxy]. It has the molecular formula C22H24C1F4O3,a relative Drug-Drug Interactions: In human liver microsome studies, gefitinib had Black 1 (2) 2 (3) GEFTINAT is contraindicated in patients with severe hypersensitivity to molecular mass of 446.9 and is a white-colored powder. Gefitinib is a noinhibitory effect on CYPIA2, CYP2C9, and CYP3A4 activities atAsian/Oriental 1 (2) 2 (3) gefitinib or to any other component of GEFTINAT. free base. concentrations ranging from 2-5000 ng/ mL. At the highest concentration Hispanic 0 (0) 3 (4) studied (5000 ng/mL),gefitinib inhibited CYP2C19 by 24% and WARNINGS Other 3 (5) 1 (1) CLINICAL PHARMACOLOGY CYP2D6 by 43%. Exposure to metoprolol, a substrate of CYP2D6, was Pulmonary Toxicity Smoking History Mechanism of Action:The mechanism of the clinical antitumor action of increased by 30% when it was given in combination with gefitinib (500 Yes (Previous or current smoker) 45 (68) 62 (82) Cases of interstitial lung disease (ILD) have been observed in patients gefitinib is not fully characterized.Gefitinib inhibits the intracellular mg daily for 28 days) in patients with solid tumors. Rifampicin, an No (Never smoked) 21 (32) 14 (18) receiving Gefitinib at an overall incidence of about 1%. Approximately phosphorylation of numerous tyrosine kinases associated with inducer of CYP3A4, reduced mean AUC of gefitinib by 85% in healthy Baseline WHO Performance Status 1/3 of the cases have been fatal. The reported incidence of ILD was transmembrane cell surface receptors, including the tyrosine kinases male volunteers (see PRECAUTIONS-Drug Interactions and DOSAGE about 2% in the Japanese post-marketing experience, about 0.3% in 0 14 (21) 9(12) associated with the epidermal growth factor receptor (EGFRTK). EGFR AND ADMINISTRATION-Dosage Adjustment sections). approximately 23,000 patients treated with Gefitinib in a US expanded 1 36 (55) 53(70) is expressed on the cell surface of many normal cells and cancer cells. Concomitant administration of itraconazole (200 mg QD for 12 days), an access program and about 1% in the studies of first-line use in NSCLC 2 15 (23) 14 (18) No clinical studies have been performed that demonstrate a correlation inhibitor of CYP3A4, with gefitinib (250 mg single dose) to healthy Not Recorded 1(2) 0(0) (but with similar rates in both treatment and placebo groups). Reports between EGFR receptor expression and response to gefitinib. male volunteers,increased mean gefitinib AUC by 88% (see Tumor Histology have described the adverse event as interstitial pneumonia, pneumonitis PRECAUTIONS-Drug Interactions section). Co-administration of high and alveolitis. Patients often present with the acute onset of dyspnea, Squamous 9(14) 11 (14) Pharmacokinetics : Gefitinib is absorbed slowly after oral administration doses of ranitidine with sodium bicarbonate (to maintain the gastric pH sometimes associated with cough or low-grade fever, often becoming Adenocarcinoma 47(71) 50 (66) with mean bioavailability of 60%. Elimination is by metabolism above pH 5.0) reduced mean gefitinib AUC by 44% (see severe within a short time and requiring hospitalization. ILD has Undifferentiated 6(9) 4 (5) (primarily CYP3A4) and excretion in feces. The elimination halt-life is PRECAUTIONS-Drug Interactions section). Large Cell 1 (2) 2(3) occurred in patients who have received prior radiation therapy (31% of about 48 hours. Daily oraladministration of gefitinib to cancer patients International Normalized Ratio (INR) elevations and/or bleeding events Squamous and Adenocarcinoma 3 (5) 7 (9) reported cases), prior chemotherapy (57% of reported patients), and no resulted in a 2- fold accumulation compared to single dose have been reported in some patients taking warfarin while on Gefitinib Not Recorded 0 (0) 2 (3) previous therapy (12% of reported cases). Patients with concurrent administration. Steady state plasma concentrations are achieved within therapy. Patients taking warfarin should be monitored regularly for idiopathic pulmonary fibrosis whose condition worsens while receiving Current DIsease Status 10 days.changes in prothrombin time or INR (see PRECAUTIONS-Drug Gefitinib have been observed to have an increased mortality compared to Locally Advanced 11 (17) 5 (7) Interactions and ADVERSE REACTIONS sections). Metastatic 55 (83) 71 (93) those without concurrent idiopathic pulmonary fibrosis. Absorption and Distribution: --------------------------------------------------------------------------- In the event of acute onset or worsening of pulmonary symptoms Gefitinib is slowly absorbed, with peak plasma levels occurring 3-7 Clinical Studies : Non-Small Cell Lung Cancer (NSCLC) - A multicenter Table 2 shows tumor response rates and response duration. The overall (dyspnea, cough, fever), Gefitinib therapy should be interrupted and a hours after dosing and mean oral bioavailability of 60%. Bioavailability clinical trial in the United States evaluated the tumor response rate of prompt investigation of these symptoms should occur. If interstitial response rate for the 250 and 500 mg doses combined was 10.6% (95% is not significantly altered by food. Gefitinib is extensively distributed Gefitinib 250 and 500 mg/day in patients with advanced non-small cell lung disease is confirmed, Gefitinib should be discontinued and the Cl: 6%, 16.8%). Response rates appeared to be highly variable in throughout the body with a mean steady state volume of distribution of lung cancer whose disease had progressed after at least two prior patient treated appropriately (see PRECAUTIONS-Information for subgroups of the treated population: 5.1% (4/79) in males, 17.5% (11/63) 1400L following intravenous administration. Invitro binding of gefitinib chemotherapy regimens including a platinumdrug and docetaxel. in females, 4.6% (5/108) in previous or current smokers, 29.4% (10/34) Patients, ADVERSE REACTIONS and DOSAGE AND to human plasma proteins (serum albumin and al-acid glycoprotein) is Gefitinib was taken once daily at approximately the same time each day.in nonsmokers, 12.4% (12/97) with adenocarcinoma histology, and 6.7% ADMINISTRATION-Dosage Adjustment sections). 90% and is independent of drug concentrations. Two hundred and sixteen patients received Gefitinib, 102 (47%) and 114 (3/45) with other NSCLC histologies. Similardifferences in response (53%) receiving 250 mg and 500 mg daily doses, respectively. Study Pregnancy Category D were seen in a multinational study in patients who had received 1 or 2 Metabolism and Elimination: Gefitinib undergoes extensive hepatic patient demographics and disease characteristics are summarized in Gefitinib may cause fetal harm when administered to a pregnant woman. prior chemotherapy regimens, at least1 of which was platinum-based. In metabolism in humans, predominantly by CYP3A4. Three sites of Table 1. Forty-one percent of the patients had received two prior responders, the median time from diagnosis to study randomization was A single dose study in rats showed that gefitinib crosses the placenta biotransformation have been identified: metabolism of the N-propoxy treatment regimens, 33% three prior treatment regimens, and 25% four 16.7 months (range 8 to 34 months). after an oral dose of 5 mg/kg (30 mg/m2 , about 1/5 the recommended morpholino-group, demethylation of the methoxy-substituent on the or more prior treatment regimens. Effectiveness of Gefitinib as third line human dose on a mg/m2basis). When pregnant rats were treated with 5 Table 2 : EfficacyResults quinazoline, and oxidative defluorination of the halogenated phenyl therapy was determined in the 142 evaluable patients with documented mg/kg from the beginning of organogenesis to the end of weaning gave --------------------------------------------------------------------------- group. Five metabolites were identified in human plasma. Only disease progression on platinum and docetaxel therapies or who had had birth, there was a reduction in the number of offspring born alive. This Avaliable Patients O-desmethyl gefitinib has exposure comparable to gefitinib. Although unacceptable toxicity on these agents. 250 mg 500 mg Combined effect was more severe at 20 mg/kg and was accompanied by high this metabolite has similar EGFR-TK activity to gefitinib in theisolated (N=66) (N=76) (N=142) neonatal mortality soon after parturition, In this study a dose of 1 enzyme assay, it had only l/14 of the potency of gefitinib in one of the Objective Tumor Response 13.6 7.9 10.6 mg/kg caused no adverse effects. cell- based assays. Rate (%) In rabbits, a dose of 20 mg/kg/day (240 mg/m2 , about twice the Gefitinib is cleared primarily by the liver, with total plasma clearance recommended dose in humans on 1 mg/m2 basis) caused reduced fetal 95% Cl (%) 6.4-24.3 3.0-16.4 6.0-16.8 and elimination half-life values of 595 mL/min and 48 hours, Median Duration of Objective weight. There are no adequate and well-controlled studies in pregnant respectively, after intravenous administration. Excretion is Response(months) 8.9 4.5 7.0 women using Gefitinib. If Gefitinib is used during pregnancy or if the predominantlyvia the feces (86%), with renal elimination of drug and Range (months) 4.6-18.6+ 4.4-7.6 4.4-18.6+ patient becomes pregnant while receiving this drug, she should be metabolites accounting for less than 4% of the administered dose. --------------------------------------------------------------------------- apprised of the potential hazard to the fetus or potential risk for loss of +=data are ongoing the pregnancy. Special Populations: In population based data analyses, no relationships Non-Small Cell Lung Cancer (NSCLC); Studies of First-line Treatment were identified between predicted steady state trough concentration and in patient age, body weight, gender, ethnicity or creatinine clearance. Combination with Chemotherapy- Two large trials were conducted in Pediatric: There are no pharmacokinetic data in pediatric patients. chemotherapy-naive patients with stage III and IV non-small cell lung cancer. Two thousand one hundred thirty patients were randomized to receive Gefitinib 250 mg daily, Gefitinib 500 mg daily, or placebo in combination with platinum-based chemotherapy regimens. The chemotherapies given in these first-line trials were gemcitabine andcis-platinum (N=1093) or carboplatin and paclitaxel (N=1037). The addition of Gefitinib did not demonstrate any increase, or trend toward such an increase, in tumor response rates, time to progression, or overall survival.PRECAUTIONS Pregnancy Table 4 - Drug Related Adverse Events 5% at 250 mg OVERDOSAGE Hepatotoxicity Pregnancy Category D (see WARNINGS and PRECAUTIONS- dose by Worst CTC Grade (n=102) The acute toxicity ofGefitinib up to 500 mg in clinical studies has Asymptomatic increases in liver transaminases have been observed in Information for Patients sections). % of patients been low. In non-clinical studies, a single dose of 12,000 mg/m2 (about Gefitinib treated patients; therefore, periodic liver function --------------------------------------------------------------------------- 80 times the recommended clinical dose on a mg/m2 basis) was lethal to (transaminases, bilirubin, and alkaline phosphatase) testing should be Nursing Mothers Adverse ALL CTC CTC CTC CTC rats. Half this dose caused no mortality in mice. considered. Discontinuation of Gefitinib should be considered if changes It is not known whether Gefitinib is excreted in human milk. Following Event Grades Grade 1 Grade 2 Grade 3 Grade 4 There is no specific treatmentfor an GEFTINAT overdose and possible are severe. oral administration of carbon-14 labeled gefitinib to rats 14 days --------------------------------------------------------------------------- symptoms of overdose are not established. However, in phase l clinical postpartum, concentrations of radioactivity in milk were higher than in Diarrhea 48 41 6 1 0 trials, a limited number of patients were treated with daily doses of up to Patients with Hepatic Impairment blood. Levels of gefitinib and its metabolites were 11-to-19-fold higher Rash 43 39 4 0 0 1000 mg. An increase in frequency and severity of some adverse In vitro and in vivo evidence suggest that gefitinib is cleared primarily in milk than in blood, after oral exposure of lactating rats to a dose of 5 Acne 25 19 6 0 0 reactions was observed, mainly diarrhea and skin rash. Adversereactions by the liver. Therefore, gefitinib exposure may be increased in patients mg/kg. Because many drugs are excreted in human milk and because of Dry Skin 13 12 1 0 0 associated with overdose should be treated symptomatically; in with hepatic dysfunction. In patients with liver metastases and the potential for serious adverse reactions in nursing infants, women Nausea 13 7 5 1 0 particular, severe diarrhea should be managed appropriately. moderately to severely elevated biochemical liver abnormalities, should be advised against breast-feeding while receiving Gefitinib Vomiting 12 9 2 1 0 however, gefitinib pharmacokinetics were similar to the therapy. Pruritus 8 7 1 0 0 DOSAGE AND ADMINISTRATION pharmacokinetics of individuals without liver abnormalities(see Anorexia 7 3 4 0 0 The recommended daily dose of GEFITINIB is one 250 mg tablet with CLINICAL PHARMACOLOGY/Pharmaco kinetics - Special Pediatric Use Asthenia 6 2 2 1 1 or without food. Higher doses do not give a better response and cause Populations section). The influence of non-cancer related hepatic Safety and effectiveness of Gefitinib in pediatric patients have not been --------------------------------------------------------------------------- increased toxicity. impairment on the pharmacokinetics of gefitinib has not been evaluated. studied. Other adverse events reported at an incidence of <5% in patients who received either 250 mg or 500 mg as monotherapy for treatment of Dosage Adjustment Information for Patients Geriatric Use NSCLC (along with their frequency at the 250 mg recommended dose) Patients with poorly tolerated diarrhea (sometimesassociated with Patients should be advised to seek medical advice promptly if they Of the total number of patients participating in trials of second- and include the following: peripheral edema (2%), amblyopia (2%), dyspnea dehydration) or skin adverse drug reactions may be successfully develop third-line Gefitinib treatment of NSCLC, 65% were aged 64 years or less, (2%), conjunctivitis (1%), vesiculobullous rash (1%), and mouth managed by providing a brief (up to 14 days) therapy interruption 1) severe or persistent diarrhea, nausea, anorexia, or vomiting, as these 30.5% were aged 65 to 74 years, and 5% of patients were aged 75 years ulceration (1%). followed by reinstatement of me 250 mg daily dose. have sometimes been associated with dehydration; or older. No differences in safety or efficacy were observed between In the event of acute onset or worsening of pulmonary symptoms 2) an onset or worsening of pulmonary symptoms, ie, shortness of breath younger and older patients. Interstitial Lung Disease (dyspnea, cough, fever), GEFTINAT therapy should be interrupted and or cough; Cases ofinterstitial lung disease (ILD) have been observed in patients a prompt investigation of these symptoms should occur and appropriate 3) an eye irritation; or, Patients with Severe Renal Impairment receivingGefitinib at an overall incidence of about l%. Approximately treatment initiated. If interstitial lung disease is confirmed, GEFTINAT 4) any other new symptom (see WARNINGS- Pulmonary Toxicity, The effect ofsevere renal impairment on the pharmacokinetics of 1/3 0f the cases have been fatal. The reported incidence of ILD was should be discontinued andthe patient treated appropriately (see ADVERSE REACTIONS and DOSAGE AND gefitinib is not known. Patients with severe renal impairment should be about 2% in the Japanese post-marketing experience, about 0.3% in WARNINGS- Pulmonary Toxicity, PRECAUTIONS-Information for ADMINISTRATION-Dosage Adjustment sections). treated with caution when given GEFTINAT. approximately 23,000 patients treated with Gefitinib in a US expanded Patients and ADVERSE REACTIONS sections). Women of childbearing potential must be advised to avoid becoming access program and about l% in the studies of first-line use in NSCLC Patients who develop onset of new eye symptoms such as pain should be pregnant (see WARNINGS-Pregnancy Category D). ADVERSE REACTIONS (but with similar rates in both treatment and placebo groups). Reports medically evaluated and managed appropriately, The safety database includes 941 patients from clinical trials and have described the adverse event asinterstitial pneumonia, pneumonitis including GEFTINAT therapy interruption and removal of an aberrant Drug Interactions approximately 23,000 patients in the Expanded Access Program. Table 3 and alveolitis. Patients often present with the acute onset of dyspnea, eyelash if present. After symptoms and eye changes have resolved, the Substances that are inducers of CYP3A4 activity increase the includes drug-related adverse events with an incidence of 5% for the 216 sometimes associated with cough or low-grade fever, often becoming decision should be made concerning reinstatement of the 250 mg daily metabolism of gefitinib and decrease its plasma concentrations. In patients who received either 250mg or 500 mg of Gefitinib monotherapy severe within a short time and requiring hospital ization. ILD has dose (see PRECAUTIONS- Information for Patients and ADVERSE patients receiving a potent CYP3A4 inducer such as rifampicin or for treatment of NSCLC. The most common adverse events reported at occurred in patients who have received prior radiation therapy (31% of REACTIONS sections), phenytoin, a dose increase to 500 mg daily should be considered in the the recommended 250 mg daily dose were diarrhea, rash, acne, dry skin, reported cases), prior chemotherapy (57% of reported patients), and no In patients receiving a potent CYP3A4 inducer such as rifampicin or absence of severe adverse drug reaction, and clinical response and nausea, and vomiting (see PRECAUTIONS- Information for Patients and previous therapy (12% of reported cases). Patients with concurrent phenytoin, a dose increase to 500 mg daily should be considered in the adverse events should be carefully monitored (see CLINICAL DOSAGE AND ADMINISTRATION- Dosage Adjustment sections). idiopathic pulmonary fibrosis whose condition worsens while receiving absence of severe adverse drug reaction, and clinical response and PHARMACOLOGY- Pharmacokinetics-Drug-Drug Interactions and The 500 mg dose showed a higher rate for most of these adverse events. Gefitinib have been observed to have an increased mortality compared to adverse events should be carefully monitored (see CLINICAL DOSAGE AND ADMIN-ISTRATION- Dosage Adjustment sections). Table 4 provides drug-related adverse events with an incidence of 5% by those without concurrent idiopathic pulmonary fibrosis. PHARMACOLOGY-Pharmacokinetics- Drug DrugInteractions and International Normalized Ratio (INR) elevations and/or bleeding events CTC grade for the patients who received the 250 mg/day dose of PRECAUTIONS-Drug Interactions sections). have been reported in some patients taking warfarin while on Gefitinib Gefitinib monotherapyfor treatment of NSCLC. Only 2% of patients In the event of acute onset or worsening of pulmonary symptoms No dosage adjustment is required on the basis of patient age, body therapy. Patients taking warfarin should be monitored regularly for stopped therapy due to an adverse drug reaction (ADR). The onset of (dyspnea, cough, fever), GEFITINIB therapy should be interrupted and a weight, gender, ethnicity, or renal function; or in patients with moderate changes in prothrombin time or INR (see CLINICAL these ADRs occurred within the first month of therapy. prompt investigation of these symptoms should occur. If interstitial lung to severe hepatic impairment due to liver metastases (see CLINICAL PHARMACOLOGY-Pharmacokinetics-Drug-Drug Interactions and disease is confirmed, Gefitinib should be discontinued and the patient PHARMACOLOGY-Pharmacokinetics- Special Populations section). ADVERSE REACTIONS sections). Table 3 - Drug-Related Adverse Events With an Incidence treated appropriately(see WARNINGS-Pulmonary Toxicity, Keepthis medication out of reach and sight of children. Substances that are potent inhibitors of CYP3A4 activity (eg, of 5% in either 250 mg or 500 mg Dose Group PRECAUTIONS- Information for Patients and DOSAGE AND ketoconazole and itraconazole) decrease gefitinib metabolism and ---------------------------------------------------------------------------ADMINISTRATION- Dosage Adjustment sections). HOW SUPPLIED increase gefitinib plasma concentra-tions. This increase may be clinically Number (%) of Patients In patients receiving Gefitinib therapy, there were reports of eye pain and 30 Tablets packed in tamper evident HDPE container. One container and relevant as adverse experiences are related to dose and exposure; --------------------------------------------------------------------------- corneal erosion/ulcer, sometimes in association with aberrant eyelash literature housed in a carton. therefore, caution should be used when administering CYP3A4 inhibitors Drug-related 250 mg/day 500 mg/day growth (see PRECAUTIONS Information for Patients section). There 10 Tablets packed in a blister. 3 blisters and literature housed in a with GEFTINAT (see CLINICAL adverse event @ (N=102) (N=114) were also rare reports of pancreatitis and very rare reports of corneal carton. PHARMACOLOGY-Pharmacokinetics-Drug-Drug Interactions and % % membrane sloughing, ocular ischemia/hemorrhage, toxic epidermal ADVERSE REACTIONS sections). Diarrhea 49 (48) 76 (67) necrolysis, erythema multiforme, and allergic reactions, including Storage Drugs that cause significant sustained elevation in gastric pH (histamine Rash 44 (43) 61 (54) angioedema and urticaria. Store in a cool, dry place, protected from light and moisture. H 2 -receptor antagonists such as ranitidine or cimetidine) may reduce Acne 25 (25) 37 (33) International Normalized Ratio (INR) elevations and/or bleeding events plasma concentrations of Gefitinib and therefore potentially may reduce Dry skin 13 (13) 30 (26) have been reported in some patientstaking warfarin while on Gefitinib Made in India by: efficacy (see CLINICAL PHARMACOLOGY- Drug-Drug Interactions Nausea 13 (13) 20 (18) therapy. Patients taking warfarin should be monitored regularly for NATCO section). Vomiting 12 (12) 10 (9) changes in prothrombin time or INR (see CLINICAL PHARMA LIMITED, Carcinogenesis, Mutagenesis, Impairment of Fertility Gefitinib has been Pruritus 8 (8) 10 (9) PHARMACOLOGY-Drug-Drug Interactions and PRECAUTIONS-Drug Regd. Office: NATCO HOUSE, ROAD No. 2, tested for genotoxicity in a series of in vitro [bacterial mutation, mouse Anorexia 7 (7) 11 (10) Interactions sections). BANJARA HILLS, HYDERABAD-500 033. lymphoma, and human lymphocyte) assays and an in vivo rat Asthenia 6 (6) 5 (4) Data from non-clinical (in vitro and in vivo) studies indicate that micronucleus test. Under the conditions of these assays, gefitinib did not Weight loss 3 (3) 6 (5) gefitinib has the potential to inhibit the cardiac action potential NATCO cause genetic damage. --------------------------------------------------------------------------- repolarization process (eg, OT interval). The clinical relevance of these Carcinogenicity studies have not been conducted with gefitinib. *A patient may have had more than 1 drugrelated adverse event. findings is unknown.对于只使用一个肿瘤专科医院或机构肝功能不全:在正常的患者(14例)，中度升高(13例)和严重升表1:人口和疾病特征适应症吉非替尼剂量 GEFTINAT* 高(4例肝转移血清谷草转氨酶(AST/SGOT)，碱性磷酸酶和胆红GEFITINAT表示作为单药治疗铂类为基础和多西紫杉醇化疗失败后 250毫克/天 500毫克/天。